Literature DB >> 6993546

Residual beta cell function in insulin-dependent diabetes: evaluation by circadian determination of C-peptide immunoreactivity.

B Canivet, M Harter, G Viot, N Balarac, B P Krebs.   

Abstract

Residual beta cell function was evaluated through circadian determination of C-peptide immunoreactivity (CPR) in eighty insulin-dependent diabetics. Evaluation of beta cell activity through circadian CPR determination was in good agreement with the results obtained by glucagon test which is considered a potent stimulus of C-peptide release. The prevalence of residual beta cell function in our population was 35%. Residual beta cell function was associated with a shorter duration of diabetes, a lower dose of insulin therapy and less chronic complications. On the other hand, serum growth hormone circadian variations were more spread in diabetics without beta cell function. That is consistent with diabetes instability which has been reported more commonly insulin-dependent diabetics without beta cell function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6993546     DOI: 10.1007/bf03348235

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

Authors:  D L Horwitz; J I Starr; M E Mako; W G Blackard; A H Rubenstein
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

2.  B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment.

Authors:  O K Faber; C Binder
Journal:  Diabetologia       Date:  1977-05       Impact factor: 10.122

3.  [Enzymatic determination of total cholesterol in serum (author's transl)].

Authors:  P Röschlau; E Bernt; W Gruber
Journal:  Z Klin Chem Klin Biochem       Date:  1974-09

4.  A fast procedure for radioimmunoassay of H.G.H.

Authors:  F Pennisi
Journal:  J Nucl Biol Med       Date:  1968 Jul-Sep

5.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

6.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

7.  C-peptide in diabetic children after stimulation with clucagon compared with fasting C-peptide levels in non-diabetic children.

Authors:  J Ludvigsson; L G Heding
Journal:  Acta Endocrinol (Copenh)       Date:  1977-06

8.  HLA-types, C-peptide and insulin antibodies in juvenile diabetes.

Authors:  J Ludvigsson; J Säfwenberg; L G Heding
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

9.  Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.

Authors:  C Hendriksen; O K Faber; J Drejer; C Binder
Journal:  Diabetologia       Date:  1977-12       Impact factor: 10.122

10.  Insulin therapy in relation to circulating C-peptide levels.

Authors:  W Beischer; W Kerner; S Raptis; L Keller; B Beischer; E F Pfeiffer
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

View more
  3 in total

1.  Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.

Authors:  S Madsbad
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

2.  Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics.

Authors:  C Giordano; A Galluzzo; F Pantò; C Caruso; G Bompiani
Journal:  Acta Diabetol Lat       Date:  1987 Oct-Dec

3.  Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1 (insulin-dependent) diabetes.

Authors:  M Knip; J Ilonen; A Mustonen; H K Akerblom
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.